Owlet (OWLT) Non-Current Deffered Revenue (2020 - 2021)
Owlet's (OWLT) quarterly Non-Current Deffered Revenue came in at $206000.0 in Q3 2021, down 97.44% year-on-year from $8.0 million in Q3 2020, and down 97.44% on a QoQ basis from $8.0 million in Q2 2021.
Owlet (OWLT) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Owlet (OWLT) has 2 years of Non-Current Deffered Revenue data on file, last reported at $206000.0 in Q3 2021.
- On a quarterly basis, Non-Current Deffered Revenue fell 97.44% year-over-year to $206000.0 in Q3 2021; TTM through Sep 2021 was $206000.0, a 97.44% decrease from a year earlier, with the FY2020 full-year figure at $322000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2021 stood at $206000.0, down from $8.0 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for OWLT reached as high as $8.0 million in Q3 2020 and fell as low as $206000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 512.79 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Owlet | 147.80 Mn | 106.79 Mn | 12.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 206,000.00 |
| Jun 30, 2021 | 8.05 Mn |
| Mar 31, 2021 | 8.05 Mn |
| Dec 31, 2020 | 322,000.00 |
| Sep 30, 2020 | 8.05 Mn |